Investigational antiviral drugs for the treatment of COVID-19 patients
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature..
In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19. A brief insight about antivirals would help clinicians to choose the best medication for the treatment of COVID-19. In this review, we discuss both novel and repurposed investigational antivirals, focusing on in vitro, in vivo, and clinical trial studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Archives of virology - 167(2022), 3 vom: 08. März, Seite 751-805 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beheshtirouy, Samineh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.03.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00705-022-05368-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336707487 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336707487 | ||
| 003 | DE-627 | ||
| 005 | 20231225232743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00705-022-05368-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336707487 | ||
| 035 | |a (NLM)35138438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beheshtirouy, Samineh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Investigational antiviral drugs for the treatment of COVID-19 patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature. | ||
| 520 | |a In the current pandemic of coronavirus disease 2019 (COVID-19), antiviral drugs are at the center of attention because of their critical role against severe acute respiratory disease syndrome coronavirus 2 (SARS-CoV-2). In addition to designing new antivirals against SARS-COV-2, a drug repurposing strategy is a practical approach for treating COVID-19. A brief insight about antivirals would help clinicians to choose the best medication for the treatment of COVID-19. In this review, we discuss both novel and repurposed investigational antivirals, focusing on in vitro, in vivo, and clinical trial studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 700 | 1 | |a Khani, Elnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Khiali, Sajad |e verfasserin |4 aut | |
| 700 | 1 | |a Entezari-Maleki, Taher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of virology |d 1980 |g 167(2022), 3 vom: 08. März, Seite 751-805 |w (DE-627)NLM000027014 |x 1432-8798 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2022 |g number:3 |g day:08 |g month:03 |g pages:751-805 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00705-022-05368-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2022 |e 3 |b 08 |c 03 |h 751-805 | ||